In an 18-hospital collaborative study, 83 newly admitted patients with a diagnosis of schizo-affective psychosis, excited state, were randomly assigned to lithium carbonate or chlorpromazine hydrochloride for a three-week period. Patients were classified as highly active or mildly active on the basis of degree of hyperactivity shown at admission.
The results showed that lithium carbonate was less effective than chlorpromazine in treating highly active patients. This was due primarily to lithium carbonate's relatively poor control of hostile, excited behavior. There was no major difference between lithium carbonate and chlorpromazine among mildly active patients; both treatments showed a significant reduction in affective and schizophrenic behavior. The possibility that lithium carbonate may have neuroleptic properties is considered in a discussion of the therapeutic and diagnostic implications of these results.
Prien RF, Caffey EM, Klett CJ. A Comparison of Lithium Carbonate and Chlorpromazine in the Treatment of Excited Schizo-Affectives: Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972;27(2):182–189. doi:10.1001/archpsyc.1972.01750260034005
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.